Study of the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the treatment of dogs with hip osteoarthritis: A prospective, block-randomized, double-blinded, placebo-controlled clinical trial

Frontiers in Veterinary Science

Veterinary Science

Thanikul Srithunyarat¹  Duangdaun Kaenkangploo¹  Naruepon Kampa¹  Supranee Jitpean¹  Suvaluk Seesupa¹  Pongsatorn Tuchpramuk²  B. Duncan X. Lascelles³  Phanthit Kamlangchai⁴  Somphong Hoisang⁴  Karn Yongvanit⁴ 

[1] Division of Surgery, Faculty of Veterinary Medicine, Khon Kaen University, Khon Kaen, Thailand;Faculty of Veterinary Sciences, Mahasarakham University, Maha Sarakham, Thailand;Translational Research in Pain Program, Comparative Pain Research and Education Centre, Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States;Center for Translational Pain Research, Department of Anesthesiology, Duke University, Durham, NC, United States;Thurston Arthritis Center, UNC, Chapel Hill, NC, United States;Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Khon Kaen University, Khon Kaen, Thailand;

关键词: OA;    marine-based fatty acid;    non-steroidal anti-inflammatory drug (NSAID);    gait analysis;    PVF;   

DOI  :  10.3389/fvets.2023.1033188

 received in 2022-08-31, accepted in 2023-01-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionGlucosamine hydrochloride and chondroitin sulfate are commonly used in dogs with OA, but evidence around efficacy is mixed. This study evaluated the effectiveness of glucosamine and chondroitin sulfate, marine based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for the alleviation of canine hip OA pain. This was a prospective, block-randomized, double-blinded, placebo-controlled clinical trial.MethodsSeventy-five owned pet dogs with hip OA were assigned randomly into five treatment groups: PCSO-524, Glucosamine and chondroitin sulfate, EAB-277, carprofen, and Placebo (sunflower oil). Peak vertical force (PVF) and subjective orthopedic assessment scores (OAS) were evaluated before treatment (week 0), and at weeks 2, 4, and 6 during treatment.ResultsAt week 2, the carprofen group showed a significant increase in PVF (3.14 ± 5.33; mean ± SD). After 4 weeks, the increases in PVF of the PCSO-524 (3.90 ± 3.52), EAB-277 (4.17 ± 4.94), and carprofen (3.08 ± 5.87) groups were significant, and significantly greater than placebo (0.08 ± 1.90) and glucosamine (−0.05 ± 6.34) groups. After 6 weeks, the change of PVF in the PCSO-524 (4.14 ± 4.65), EAB-277 (4.45 ± 4.23), and carprofen (4.21 ± 6.52) groups were significant and significantly higher than the placebo group (−0.33 ± 3.65). The change in PVF in the glucosamine group (1.08 ± 5.49) lay between the placebo group and the other treatment groups. The OAS did not show any significant change in any group.DiscussionPCSO-524 and EAB-277, but not glucosamine/chondroitin, resulted in significant improvements in PVF from baseline after 4 weeks, and 6 weeks, and to a similar degree to that seen with carprofen.

【 授权许可】

Unknown   
Copyright © 2023 Kampa, Kaenkangploo, Jitpean, Srithunyarat, Seesupa, Hoisang, Yongvanit, Kamlangchai, Tuchpramuk and Lascelles.